CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
CMLH1P536FSOncogenicSupportsOncogenicityColorectal CancerGeurts-Giele et al., 2014
CMLH1G67ROncogenicSupportsOncogenicityColorectal CancerGeurts-Giele et al., 2014
CMLH1I68SOncogenicSupportsOncogenicityColorectal CancerGeurts-Giele et al., 2014
CMLH1G65DOncogenicSupportsOncogenicityColorectal CancerGeurts-Giele et al., 2014
CMLH1A681VOncogenicSupportsOncogenicityColorectal CancerGeurts-Giele et al., 2014
CMSH6P138TOncogenicSupportsOncogenicityColorectal CancerGeurts-Giele et al., 2014
CMSH2V273FSOncogenicSupportsOncogenicityColorectal CancerGeurts-Giele et al., 2014
CMSH2E28FSOncogenicSupportsOncogenicityColorectal CancerGeurts-Giele et al., 2014
CVHLE55FS (c.163_164delGA)OncogenicSupportsOncogenicityRenal Cell CarcinomaGallou et al., 1999
CMSH6I891FSOncogenicSupportsOncogenicityColorectal CancerGeurts-Giele et al., 2014
CMSH6R1242HOncogenicSupportsOncogenicityColorectal CancerGeurts-Giele et al., 2014
CPMS2R315*OncogenicSupportsOncogenicityEndometrial CancerGeurts-Giele et al., 2014
CMLH1M490TOncogenicSupportsOncogenicityEndometrial CancerGeurts-Giele et al., 2014
CMSH2K172*OncogenicSupportsOncogenicityColorectal CancerGeurts-Giele et al., 2014
CMSH2E483GOncogenicSupportsOncogenicityEndometrial CancerGeurts-Giele et al., 2014
CMSH6V352IOncogenicSupportsOncogenicityEndometrial CancerGeurts-Giele et al., 2014
CMSH6R1242COncogenicSupportsOncogenicityColorectal CancerGeurts-Giele et al., 2014
CBRAFV600E AND ARAF S490TPredictiveSupportsResistanceColorectal CancerCetuximab,Vemurafenib,IrinotecanHong et al., 2016
CVHLM54IFS (c.162_166delGGAGG)OncogenicSupportsOncogenicityClear Cell Renal Cell CarcinomaShuin et al., 1994
CPTENR173COncogenicSupportsOncogenicityEndometrial HyperplasiaMaxwell et al., 1998
CVHLM1FS (c.1_17del17)OncogenicSupportsOncogenicityChromophobe Renal Cell Carcinomavan Houwelingen et al., 2005
CVHLM1? (c.1-1_20del21)OncogenicSupportsOncogenicityClear Cell Renal Cell Carcinomavan Houwelingen et al., 2005
CVHLM1? (c.3G>A)OncogenicSupportsOncogenicityClear Cell Renal Cell CarcinomaGallou et al., 2001
CVHLN7D (c.19A>G)OncogenicSupportsOncogenicityRenal Cell CarcinomaMa et al., 2001
CVHLY98FS (c.291_310del20)OncogenicSupportsOncogenicityClear Cell Renal Cell Carcinomavan Houwelingen et al., 2005
DMTAPUnderexpressionPredictiveSupportsSensitivity/ResponseBreast CancerPyrimidine Antagonistde Oliveira et al., 2016
DERBB2T862APredictiveSupportsSensitivity/ResponseCancerLapatinibKancha et al., 2011
DPIK3CAE542KPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPI-103O'Brien et al., 2010
CNRASG13RPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
CKITF506_F508DUPPredictiveDoes Not SupportSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2008
CKITK484_G487DELPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2008
CPDGFRAV561DPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2008
CPDGFRAExon 18 MutationPredictiveDoes Not SupportSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2008
CEGFRL858RPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaGefitinibPao et al., 2004
CTP53MutationPredictiveSupportsResistanceBreast CancerTamoxifenBerns et al., 2000
CTP53MutationPredictiveSupportsSensitivity/ResponseStomach CarcinomaCisplatin,Etoposide,DoxorubicinBataille et al., 2003
DBCR::ABL1Fusion AND ABL1 L384MPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib Mesylate,NilotinibBradeen et al., 2006
CROS1G2032RPredictiveSupportsResistanceLung AdenocarcinomaCrizotinibAwad et al., 2013
BNTRK1Amplification OR NTRK3 Amplification OR NTRK2 AmplificationPredictiveDoes Not SupportSensitivity/ResponseCancerEntrectinibDrilon et al., 2017
BNTRK3AmplificationPredictiveDoes Not SupportSensitivity/ResponseCancerEntrectinibDrilon et al., 2017
CVHLW8* (c.24G>A)OncogenicSupportsOncogenicityRenal Cell CarcinomaMa et al., 2001
BCTNNB1S45PPrognosticSupportsBetter OutcomeDesmoid TumorLazar et al., 2008
BPIK3CAH1047R OR PIK3CA H1047LPrognosticSupportsPoor OutcomeBreast Tubular CarcinomaCheng et al., 2017
CBCR::ABL1Fusion AND ABL1 F359VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 F359VPredictiveSupportsReduced SensitivityChronic Myeloid LeukemiaDasatinibGuilhot et al., 2007
CNRASG13RPredictiveSupportsResistanceColorectal CancerPanitumumabDe Roock et al., 2010
CHRASG13DPredictiveSupportsResistanceSkin Squamous Cell CarcinomaVemurafenibSu et al., 2012
DKRASG13DPredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
DKRASG12DPredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
DKRASG12RPredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
Page 91 of 96
PreviousNext